Aeglea, Mirna, Cancer Prevention & Research Institute of Texas (CPRIT) cancer news

CPRIT awarded three-year grants totaling up to about $45 million to cancer companies Mirna and Aeglea. Mirna will receive up to $25.1 million to develop compounds that mimic naturally occurring tumor suppressor microRNAs. The company's MRX34 - a synthetic mimic of miR-34, a naturally occurring tumor suppressor, formulated with lipid-based nanoparticles - is in Phase I testing for primary liver cancer. Aeglea will receive up to $19.8 million to develop AERase, an engineered human arginase 1 (ARG1) in preclinical testing for solid tumors. ...